CMS Expands Ambulatory Blood Pressure Monitoring Coverage
The US Medicare agency has decided that evidence is sufficient to cover ambulatory blood pressure monitoring to help diagnose hypertension in beneficiaries who suffer from white coat high blood pressure, and those with suspected masked hypertension.
You may also be interested in...
White Coat, Masked Hypertensives Could Win Ambulatory Blood Pressure Monitoring Coverage Under CMS Proposal
An April 9 proposed decision memo from the US Centers for Medicare and Medicaid Services would allow additional coverage for use of ambulatory blood pressure monitoring (APBM) devices by Medicare beneficiaries with known or suspected high blood pressure who meet specific criteria defined by the agency.
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
Roughly 18.5% of patients who received reinterventions to fix mesh implants for pelvic organ prolapse (POP) repair experienced complications they will likely endure for the rest of their lives, and they also face a 2.5% higher rate of further surgeries than non-mesh patients, says a recent 54,194-woman study detailed in Obstetrics & Gynecology. The study authors lay out a case that the US FDA should have forced removal of mesh from the market sooner.